Tag Archives: gild

Achillion Dives As J&J Hep C Deal Chills Buyout Buzz

Analysts gave mixed reviews Wednesday to Achillion Pharmaceuticals’ (ACHN) new partnership with Johnson & Johnson (JNJ), as the stock plunged. UBS and JMP Securities both downgraded the stock to neutral as the potential for a massive value-creating event, like a buyout, is limited by the hepatitis-C drug deal. As recently as Monday, Achillion Pharmaceuticals shares shot up 15.3% on buzz that hepatitis-C giant Gilead Sciences (GILD) might buy the

Move Over Chip Stocks: Here Are 5 Top Biotechs

From new product introductions to swiped trade secrets, chipmakers have stolen the spotlight so far this week. But let’s not forget about biotech stocks, five of which are highlighted in IBD’s Screen of the Day, Big Cap Leaders, along with their semiconductor counterparts. The large-cap biotechs include Celgene (CELG), Regeneron Pharmaceuticals (REGN) and Gilead Sciences (GILD) Celgene, which has a highest-possible IBD Composite Rating of 99,

LinkedIn Checks Out, Solars Eclipsed, Tesla Powers Up

After-hours action was busy, with LinkedIn (LNKD) continuing social networks’ poorly received reports, solar stocks falling short on revenue and Gilead Sciences (GILD) crushing estimates on its latest hepatitis drug. Meanwhile, Tesla Motors (TSLA) awaited its much-hyped battery announcement. LinkedIn stock shares plummeted 21% in late trading despite a first-quarter beat, as the social media site for professionals provided weak Q2 earnings and